Fluicell AB (OSTO:FLUI) Current Accrued Expense: kr0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:FLUI Fluicell AB OSTO:FLUI
47 GF Score
Price kr31.30
GF Value kr80.53
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Fluicell AB Current Accrued Expense?

Fluicell AB OSTO:FLUI 47 Current Accrued Expense is kr0.00 Mil as of Jun. 2026. GuruFocus rates OSTO:FLUI with a GF Score™ of 47/100 and a GF Value™ of kr80.53 (Possible Value Trap). The stock has 4 warning signs investors should review.

Fluicell AB's Current Accrued Expense for the quarter that ended in Jun. 2026 was kr0.00 Mil.

Fluicell AB Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Fluicell AB's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fluicell AB Current Accrued Expense Chart

Fluicell AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Fluicell AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:FLUI
47GF Score
Fluicell AB OSTO:FLUI
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fluicell AB Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of kr0.00 Mil mean?
Fluicell AB (OSTO:FLUI) has a Current Accrued Expense of kr0.00 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Fluicell AB and its competitors.
Is Fluicell AB's Current Accrued Expense too high?
Fluicell AB's current Current Accrued Expense is kr0.00 Mil. Overall, Fluicell AB has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Fluicell AB's Current Accrued Expense compare to VRTX and REGN?
Fluicell AB's Current Accrued Expense of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Fluicell AB and its competitors. Fluicell AB's current Current Accrued Expense is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fluicell AB stock overvalued right now?
Based on GuruFocus' analysis, Fluicell AB (OSTO:FLUI) is currently considered Possible Value Trap. The stock's GF Value™ is kr80.53, compared to a current price of kr31.30 — trading 61.1% below its estimated fair value. The current Current Accrued Expense is kr0.00 Mil. Fluicell AB's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Fluicell AB (OSTO:FLUI), the current Current Accrued Expense is kr0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fluicell AB (OSTO:FLUI) Overvalued in 2026?

Based on GuruFocus' analysis, Fluicell AB stock appears to be undervalued. The current stock price of kr31.30 is trading 61.1% below its estimated GF Value™ of kr80.53. GuruFocus considers Fluicell AB to be Possible Value Trap.

Key valuation signals for OSTO:FLUI:

  • Current Accrued Expense: kr0.00 Mil
  • GF Value™: kr80.53 vs. price of kr31.30 (61.1% below fair value)
  • GF Score™: 47/100 with 4 warning signs

No single metric tells the full story. See the OSTO:FLUI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fluicell AB Business Description

Other Exchanges 5J90:Germany
Address Flojelbergsgatan 8C, Molndal, Gothenburg, SWE, 431 37
Fluicell AB is a Swedish life science company that conducts development in regenerative medicine and human tissue-based screening models for drug development, with a particular focus on the areas of type 1 diabetes, cardiac safety screening models, and kidney diseases. The company's platform for the production of human tissue that is based on Fluicell's technology for high-resolution 3D bioprinting, and which enables the creation of tissue-based products for use in drug development and regenerative medicine.
47GF Score

Get the complete analysis for OSTO:FLUI

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr31.30
Price
kr80.53
GF Value